You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Government & Policy Articles
Popular Government & Policy Articles
Highly Recommended Government & Policy Articles
Send a link to this page to your friends and colleagues.
The U.S. Food and Drug Administration has approved Diovan (valsartan), a medication for high blood pressure, to treat heart failure in people who cannot tolerate ACE (angiotensin-converting-enzyme) inhibitors.
Diovan, an angiotension II receptor blocker (ARB), is the first drug in its class to gain approval for therapy beyond controlling blood pressure, according to a news release from Novartis, of East Hanover, New Jersey, which makes the drug.
"Nearly five million Americans have heart failure, and 1,500 new cases are discovered every day," Jay N. Cohn, MD, noted in the news release. Cohn is professor of medicine in the Cardiovascular Division of the University of Minnesota Medical School and lead investigator of the Valsartan Heart Failure Trial (Val-HeFT).
Heart failure is caused by many factors, including a heart attack or other injury to the heart, abnormalities in heart valves or muscle walls, clogged arteries or long-term high blood pressure.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.